Galectins (GAL) are a family of endogenous glycan-binding proteins, among which, GAL1, GAL3 and GAL9 can be seen in many types of cancer progression and is considered to be a promising molecular target for the development of cancer therapeutic drugs [55, 56]. This evidence concerns the gene LGALS3 and cancer.